SEC EDGARSEP 41 min read$AXGN

TYNDALL JOSEPH A. sold $174K of AXGN

TYNDALL JOSEPH A. sold 3,500 shares of Axogen, Inc. (AXGN) at $49.70 ($0.17M total) on 2026-09-02 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · TYNDALL JOSEPH A.

Published Sep 4, 2026, 8:08 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 4, 2026, 8:19 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$AXGN

Neutral

medium confidence

Mentioned

$AXGN

Relevance

3/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$AXGNNeutralLow

Why it matters

The sale is modest and pre‑arranged, suggesting low informational content for traders.

Market read

Limited relevance; likely no immediate price impact.

What to watch

Potential upcoming clinical data or financing needs not disclosed.

Relevance 3/10Novelty 4/10Timing: filing posted on 2026-09-04, sale dated 2026-09-02

Background

Form 4 filings disclose insider transactions; director sales are monitored for potential signals.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$AXGNNeutralMedium confidence

Context

Director Joseph Tyndall sold 3,500 shares of Axogen for $173,939.50 on 2026-09-02 via a 10b5‑1 plan.

Expected impact

Minimal short‑term price pressure; likely absorbed without significant move.

Evidence & confidence

The transaction size (~$174k) is low for a director and executed under a pre‑arranged plan, reducing informational value.

Market effects

Sector

None significant for the broader biotech sector.

Regional

No regional effect.

Global

Limited to Axogen shareholders.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event rather than a negative signal.

Key entities

Company
Axogen, Inc.
US‑listed biotech (NASDAQ: AXGN) developing nerve repair technologies.
Individual
Joseph Tyndall
Director of Axogen executing a 10b5‑1 sale.

Read at source ← All news

SEP 11

$JNJMedAI 8/10

Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials

Johnson & Johnson (JNJ) received CE Marking for ACUVUE OASYS MAX 2-Week contact lenses. GSK (GSK) expanded Shingrix approval in Japan. Axogen (AXGN) to acquire BioCircuit for $200M. Femasys (FEMY) partnered with CapexMD for fertility financing. EpilepsyGTx collaborated with Viralgen (BAYN.DE) for gene therapy. HCW Biologics (HCWB) partnered with Akron Biotech. Bluejay Diagnostics (BJDX) teamed with Lovell for federal market access. Transgene (TNG.PA) expanded partnership with ProBioGen. Oncolyti

rttnews.com3 min

SEP 10

$AXGNHighAI 9/10

Why is Axogen stock sliding today?

Axogen (AXGN) stock fell 9.0% in pre-market trading after announcing a $200M acquisition of BioCircuit Technologies and a $208.7M equity raise at a 10% discount. The deal includes a 30-day over-allotment option. Axogen expects the acquisition to boost revenue, EBITDA, and earnings. The stock drop is attributed to the discounted equity offering.

investing.com2 min

SEP 10

$AXGNHighAI 9/10

Axogen, Inc.: Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies

Axogen (AXGN) agreed to acquire BioCircuit Technologies for $200M, adding NerveTape, an FDA-approved sutureless nerve repair device. The deal is expected to boost revenue, EBITDA, and EPS while maintaining positive cash flow. Axogen plans to fund the acquisition with proceeds from a common stock offering. The transaction is set to close in Q4 2026, subject to conditions.

finanznachrichten.de2 min

AUG 26

$ARGXMed

Here Are Wednesday’s Top Wall Street Analyst Research Calls: Atlassian, Dick’s Sporting Goods, EPAM Systems, GoDaddy, Intuit, Jersey Mike’s Subs, JFrog, Lattice Semiconductor, and More

Wall Street analysts issued upgrades, downgrades, and initiations for several companies. Upgrades include argenx (ARGX) to Buy at UBS, DT Midstream (DTM) to Outperform at Wolfe Research, and SolarEdge (SEDG) to Buy at UBS. Downgrades include Dick's Sporting Goods (DKS) to Hold at Truist, EPAM Systems (EPAM) to Neutral at JPMorgan, and Intuit (INTU) to Neutral at Bank of America. Initiations include Atlassian (TEAM) with Outperform at RBC, JFrog (FROG) with Outperform at RBC, and Lattice Semicond

247wallst.com4 min

AUG 8

$AXGNMedAI 8/10

Axogen (AXGN) Q2 2026 Earnings Call Transcript

Axogen (AXGN) reported Q2 2026 revenue of $69.7 million, up 23.1% year over year, driven by growth in breast, extremities, and OMF. Breast revenue grew more than 50% and contributed about two-thirds of growth. Gross margin was 72.7%. Adjusted net income was $7.3 million ($0.12/share). Full-year revenue guidance raised to at least $279 million (24% growth) and gross margin to at least 73%.

fool.com6 min

JUL 29

$AXGNMed

Axogen, Inc. (AXGN): Results of Operations and Financial Condition

Axogen, Inc. (AXGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Axogen, Inc. Reports Second Quarter 2026 Financial Results Raises Full Year Revenue Guidance to at Least 24% Growth or $279 million ALACHUA and TAMPA, FL – July 29, 2026 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical so

SEC EDGAR 8-K3 min